The effects of alendronate and Vitamin K on postmenopausal osteoporosis
Phase 3
- Conditions
- Osteoporosis.postmenopausal osteoporosis
- Registration Number
- IRCT201504141479N3
- Lead Sponsor
- Vice president for research, Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 50
Inclusion Criteria
1- Osteoporosis according to WHO Criteria
2-Age:45-65 years
3- Postmenopausal women
Exclusion criteria
1- Secondary Osteoporosis
2- Taking anticoagulants
3- History of liver and kidney disorders
4- History of Bisphosphonates side effects
5- People who have contraindications to take calcium and vitamin D
6- People who take other anti- osteoporotic medications
7- People who needs to use Vit.K in the alendronate group
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Bone mineral density. Timepoint: Before the intervention and one year later. Method of measurement: By Densitometery with DXA method.
- Secondary Outcome Measures
Name Time Method Drug side effects. Timepoint: Every 2 months. Method of measurement: Taking history.